Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle, MM Borbath, I Clarke, SJ Hitre, E Louvet, C Mercade, TM Oh, DY Spratlin, JL Weiss, KH
Javle, MM
Borbath, I
Clarke, SJ
Hitre, E
Louvet, C
Mercade, TM
Oh, DY
Spratlin, JL
Weiss, KH
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Javle MM, Borbath I, Clarke SJ, Hitre E, Louvet C, Mercade TM, et al. Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. J Clin Oncol. 2019;37(15_suppl):TPS4155-TPS.